Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / IUGNF - Imugene doses first patient in PD1-Vaxx combination trial

IUGNF - Imugene doses first patient in PD1-Vaxx combination trial

Imugene Ltd

(NewsDirect)

Imugene Ltd (ASX:IMU) managing director and CEO Leslie Chong speakswith Proactive soon after announcing the first patient has been dosedin the combination cohort of the IMPRINTER study - a clinical trial toevaluate the safety and efficacy of Imugene’s PD1- Vaxx incombination with atezolizumab (Tecentriq®) in patients with non-smallcell lung cancer. She says Tecentriq® has previously shown clinicallymeaningful benefit in various types of lung cancer, with six currentlyapproved indications in the US.

ContactDetails

Proactive Investors

JonathanJackson

+61 413 713 744

Jonathan@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.

Stock Information
Company Name: Imugene Ltd
Stock Symbol: IUGNF
Market: OTC
Menu
IUGNF IUGNF Quote IUGNF Short IUGNF News IUGNF Articles IUGNF Message Board
Get IUGNF Alerts

News, Short Squeeze, Breakout and More Instantly...